Valsartan MDL Judge Denies Defense Motion For Litigation Funding Disclosure

Mealey's (September 30, 2019, 1:03 PM EDT) -- CAMDEN, N.J. — The New Jersey federal judge overseeing the valsartan multidistrict litigation on Sept. 18 denied a motion by multiple defendants to require plaintiffs to disclose if they are being financial backed by litigation funding, finding that the information is irrelevant and that there’s no showing that lawsuit financiers are real parties-in-interest that control the litigation (In Re:  Valsartan N-Nitrosodimethylamine Litigation, MDL Docket No. 2875, No. 19-2875, D. N.J., Camden Vicinage)....

Attached Documents

Related Sections